$3250 | Single User
$6500 | Site License
$9750 | Enterprise License

Multiple Myeloma -Epidemiology Forecast to 2027
[Report Updated: 14-02-2018]

Published by Delve Insight: 14 Feb 2018 | 201671 | In Stock
Related Topics: Multiple Myeloma , Myeloma

Introduction

DelveInsight's "Multiple Myeloma - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Multiple Myeloma epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

Markets Covered

• United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2016-2027

Multiple Myeloma Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Multiple Myeloma in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Multiple Myeloma outlook. It also includes the explanation of changing trends of epidemiology outlining the Multiple Myeloma scenario.

Multiple Myeloma Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Multiple Myeloma thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

• The report covers detailed overview of Multiple Myeloma explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

• The Multiple Myeloma Report assesses the disease risk and burden and highlights the unmet needs

• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

• 10 Year Forecast

• 7MM Coverage

• Total Cases in Multiple Myeloma

Key assessments

• Patient Segmentation in Multiple Myeloma

• Multiple Myeloma Risk & Burden

• Factors driving growth in a specific Multiple Myeloma patient population

Table of Contents
for Multiple Myeloma -Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

  • 1. Report Introduction

    2. Multiple Myeloma Epidemiology Overview at a Glance

    2.1. Patient Share Distribution of Multiple Myeloma in 2017

    2.2. Patient Share Distribution of Multiple Myeloma in 2027

    3. Disease Background and Overview: Multiple Myeloma

    3.1. Introduction

    3.2. Symptoms

    3.3. Etiology

    3.4. Risk Factors

    3.5. Pathophysiology

    3.6. Diagnosis

    3.7. Treatment

    4. Epidemiology and Patient Population

    4.1. Key Findings

    4.2. Total Prevalent/ Incident Patient Population of Multiple Myeloma in 7MM

    4.3. Total Prevalent/ Incident Patient Population of Multiple Myeloma in 7MM – By Countries

    5. Epidemiology of Multiple Myeloma by Countries

    5.1. United States

    5.1.1. Assumptions and Rationale

    5.1.2. Prevalent/Incident Cases of the Multiple Myeloma

    5.1.3. Sub-Type Specific cases of the Multiple Myeloma *

    5.1.4. Sex- Specific Cases of the Multiple Myeloma*

    5.1.5. Diagnosed Cases of the Multiple Myeloma

    5.2. EU5

    5.3. Assumptions and Rationale

    5.4. Germany

    5.4.1. Assumptions and Rationale

    5.4.2. Prevalent/Incident Cases of the Multiple Myeloma

    5.4.3. Sub-Type Specific cases of the Multiple Myeloma*

    5.4.4. Sex- Specific Cases of the Multiple Myeloma*

    5.4.5. Diagnosed Cases of the Multiple Myeloma

    5.5. France

    5.5.1. Assumptions and Rationale

    5.5.2. Prevalent/Incident Cases of the Multiple Myeloma

    5.5.3. Sub-Type Specific cases of the Multiple Myeloma*

    5.5.4. Sex- Specific Cases of the Multiple Myeloma*

    5.5.5. Diagnosed Cases of the Multiple Myeloma

    5.6. Italy

    5.6.1. Assumptions and Rationale

    5.6.2. Prevalent/Incident Cases of the Multiple Myeloma

    5.6.3. Sub-Type Specific cases of the Multiple Myeloma*

    5.6.4. Sex- Specific Cases of the Multiple Myeloma*

    5.6.5. Diagnosed Cases of the Multiple Myeloma

    5.7. Spain

    5.7.1. Assumptions and Rationale

    5.7.2. Prevalent/Incident Cases of the Multiple Myeloma

    5.7.3. Sub-Type Specific cases of the Multiple Myeloma*

    5.7.4. Sex- Specific Cases of the Multiple Myeloma*

    5.7.5. Diagnosed Cases of the Multiple Myeloma

    5.8. United Kingdom

    5.8.1. Assumptions and Rationale

    5.8.2. Prevalent/Incident Cases of the Multiple Myeloma

    5.8.3. Sub-Type Specific cases of the Multiple Myeloma*

    5.8.4. Sex- Specific Cases of the Multiple Myeloma*

    5.8.5. Diagnosed Cases of the Multiple Myeloma

    5.9. Japan

    5.9.1. Assumptions and Rationale

    5.9.2. Prevalent/Incident Cases of the Multiple Myeloma

    5.9.3. Sub-Type Specific cases of the Multiple Myeloma*

    5.9.4. Sex- Specific Cases of the Multiple Myeloma*

    5.9.5. Diagnosed Cases of the Multiple Myeloma

    6. Unmet Needs of the Multiple Myeloma

    7. Appendix

    8. Report Methodology

    8.1. Sources

    9. DelveInsight Capabilities

    10. Disclaimer

    11. About DelveInsight

    *Indication Specific

List Of Tables
in Multiple Myeloma -Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

Table 1: Total Prevalent/Incident Cases of the Multiple Myeloma in 7MM

Table 2: Total Prevalent/Incident Cases of the Multiple Myeloma in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Multiple Myeloma in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Multiple Myeloma in United States (2016-2027)*

Table 5: Sex- Specific Cases of the Multiple Myeloma in United States (2016-2027)*

Table 6: Diagnosed Cases of the Multiple Myeloma in United States (2016-2027)

Table 7: Prevalent/Incident Cases of the Multiple Myeloma in Germany (2016-2027)

Table 8: Sub-Type Specific cases of the Multiple Myeloma in Germany (2016-2027) *

Table 9: Sex- Specific Cases of the Multiple Myeloma in Germany (2016-2027) *

Table 10: Diagnosed Cases of the Multiple Myeloma in Germany (2016-2027)

Table 11: Prevalent/Incident Cases of the Multiple Myeloma in France (2016-2027)

Table 12: Sub-Type Specific cases of the Multiple Myeloma in France (2016-2027) *

Table 13: Sex- Specific Cases of the Multiple Myeloma in France (2016-2027) *

Table 14: Diagnosed Cases of the Multiple Myeloma in France (2016-2027)

Table 15: Prevalent/Incident Cases of the Multiple Myeloma in Italy (2016-2027)

Table 16: Sub-Type Specific cases of the Multiple Myeloma in Italy (2016-2027) *

Table 17: Sex- Specific Cases of the Multiple Myeloma in Italy (2016-2027) *

Table 18: Diagnosed Cases of the Multiple Myeloma in Italy (2016-2027)

Table 19: Prevalent/Incident Cases of the Multiple Myeloma in Spain (2016-2027)

Table 20: Sub-Type Specific cases of the Multiple Myeloma in Spain (2016-2027) *

Table 21: Sex- Specific Cases of the Multiple Myeloma in Spain (2016-2027) *

Table 22: Diagnosed Cases of the Multiple Myeloma in Spain (2016-2027)

Table 23: Prevalent/Incident Cases of the Multiple Myeloma in UK (2016-2027)

Table 24: Sub-Type Specific cases of the Multiple Myeloma in UK (2016-2027) *

Table 25: Sex- Specific Cases of the Multiple Myeloma in UK (2016-2027) *

Table 26: Diagnosed Cases of the Multiple Myeloma in UK (2016-2027)

Table 27: Prevalent/Incident Cases of the Multiple Myeloma in Japan (2016-2027)

Table 28: Sub-Type Specific cases of the Multiple Myeloma in Japan (2016-2027) *

Table 29: Sex- Specific Cases of the Multiple Myeloma in Japan (2016-2027) *

Table 30: Diagnosed Cases of the Multiple Myeloma in Japan (2016-2027)

List Of Figures, Charts and Diagrams
in Multiple Myeloma -Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

Table 1: Total Prevalent/Incident Cases of the Multiple Myeloma in 7MM

Table 2: Total Prevalent/Incident Cases of the Multiple Myeloma in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Multiple Myeloma in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Multiple Myeloma in United States (2016-2027)*

Table 5: Sex- Specific Cases of the Multiple Myeloma in United States (2016-2027)*

Table 6: Diagnosed Cases of the Multiple Myeloma in United States (2016-2027)

Table 7: Prevalent/Incident Cases of the Multiple Myeloma in Germany (2016-2027)

Table 8: Sub-Type Specific cases of the Multiple Myeloma in Germany (2016-2027) *

Table 9: Sex- Specific Cases of the Multiple Myeloma in Germany (2016-2027) *

Table 10: Diagnosed Cases of the Multiple Myeloma in Germany (2016-2027)

Table 11: Prevalent/Incident Cases of the Multiple Myeloma in France (2016-2027)

Table 12: Sub-Type Specific cases of the Multiple Myeloma in France (2016-2027) *

Table 13: Sex- Specific Cases of the Multiple Myeloma in France (2016-2027) *

Table 14: Diagnosed Cases of the Multiple Myeloma in France (2016-2027)

Table 15: Prevalent/Incident Cases of the Multiple Myeloma in Italy (2016-2027)

Table 16: Sub-Type Specific cases of the Multiple Myeloma in Italy (2016-2027) *

Table 17: Sex- Specific Cases of the Multiple Myeloma in Italy (2016-2027) *

Table 18: Diagnosed Cases of the Multiple Myeloma in Italy (2016-2027)

Table 19: Prevalent/Incident Cases of the Multiple Myeloma in Spain (2016-2027)

Table 20: Sub-Type Specific cases of the Multiple Myeloma in Spain (2016-2027) *

Table 21: Sex- Specific Cases of the Multiple Myeloma in Spain (2016-2027) *

Table 22: Diagnosed Cases of the Multiple Myeloma in Spain (2016-2027)

Table 23: Prevalent/Incident Cases of the Multiple Myeloma in UK (2016-2027)

Table 24: Sub-Type Specific cases of the Multiple Myeloma in UK (2016-2027) *

Table 25: Sex- Specific Cases of the Multiple Myeloma in UK (2016-2027) *

Table 26: Diagnosed Cases of the Multiple Myeloma in UK (2016-2027)

Table 27: Prevalent/Incident Cases of the Multiple Myeloma in Japan (2016-2027)

Table 28: Sub-Type Specific cases of the Multiple Myeloma in Japan (2016-2027) *

Table 29: Sex- Specific Cases of the Multiple Myeloma in Japan (2016-2027) *

Table 30: Diagnosed Cases of the Multiple Myeloma in Japan (2016-2027)

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

201671 | DIEI0321

Number of Pages

50

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Physician Views: Sanofi's Lemtrada finally approved in the US – how will neurologists use the multiple sclerosis therapy?
Scope Two years after it was first submitted for approval with the FDA, Sanofi's multiple sclerosis ...
25 Nov 2014 by FirstWord Pharma USD $695 More Info
KOL Insight: Multiple Sclerosis
IntroductionRecent launches of oral therapies have brought clinical advantages and clear patient ben...
06 Oct 2014 by FirstWord Pharma USD $7,900 More Info
Physician Views: How do neurologists value multiple sclerosis medical affairs teams – what could they be doing better?
Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
18 Jun 2014 by FirstWord Pharma USD $695 More Info
Physician Views: What drives physician brand loyalty in the ultra-competitive multiple sclerosis market?
Scope The multiple sclerosis market is arguably one of the most competitive in pharma, shaped in par...
05 May 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Life-cycle management strategies in multiple sclerosis – can new versions of Copaxone, Avonex drive market share retention?
Scope With Copaxone and Avonex generating global sales of .3 billion and billion for Teva and B...
26 Mar 2014 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis: KOL Insight
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
01 Dec 2013 by FirstWord Pharma USD $7,900 More Info
Consensus Outlook: Multiple Sclerosis
IntroductionOver the next five years, the global multiple sclerosis (MS) market is set to grow from ...
01 Dec 2013 by FirstWord Pharma USD $4,995 More Info
Physician Views – Which multiple sclerosis players do the best marketing job? – FirstWord polls neurologists in the US and 5EU
ScopeThe multiple sclerosis market has undergone notable change over the past 2 years, primarily due...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Sanofi secures EU approval for its multiple sclerosis treatment Lemtrada – how will neurologists use it?
ScopeWith Sanofi securing European approval for its multiple sclerosis therapy Lemtrada last week, n...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
12 Mar 2013 by FirstWord Pharma USD $7,495 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

Multiple Myeloma -Epidemiology Forecast to 2027 [Report Updated: 14-02-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...